[Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers].
The 'Stichting Werkgroep Antibioticabeleid' (SWAB; Dutch Working Party on Antibiotics Policy) has developed evidence-based guidelines for the antimicrobial treatment of methicillin-resistant Staphylococcus aureus (MRSA) carriers for the eradication of MRSA. A distinction was made between uncomplicated and complicated carriage depending on the presence or absence of an active MRSA infection, skin lesions, foreign body material, mupirocin resistance and/or extranasal carriage. The indication for treatment is determined by the consequences of carriage for the carrier and his/her environment, the adverse events of treatment, and the likelihood of a successful treatment. The first choice of treatment in uncomplicated carriers is a combination of mupirocin nasal ointment and disinfectant soap for 5 days, along with hygiene advice. If treatment fails, sources in the vicinity of the patient must be sought. Complicated carriers receive a combination of 2 oral antibiotics, in addition to mupirocin nasal ointment and disinfectant soap, for at least 7 days.
Wertheim
H F L
HF
Erasmus MC-Centrum, afd. Medische Microbiologie en Infectieziekten, Rotterdam.
Ammerlaan
H S M
HS
Bonten
M J M
MJ
van den Broek
P J
PJ
Troelstra
A
A
Vandenbroucke-Grauls
C M J E
CM
Vos
M C
MC
Voss
A
A
Nouwen
J L
JL
Kluytmans
J A J W
JA
D002353:Carrier State; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006920:Hygiene; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D016712:Mupirocin / Q000627:therapeutic use*; D009296:Nasal Cavity / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
D016712:Mupirocin